GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3

by Joy Lin
Share To

Pfizer and Astellas have announced their prostate cancer therapy, Xtandi (enzalutamide), has achieved its main objectives in a Phase 3 trial. 

The latest trial win comes days after Astellas announced a success in the Arches study of Xtandi plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). 

Xtandi has been approved for the treatment of mHSPC, metastatic castration-resistant prostate cancer (mCRPC) and its non-metastatic form (nmCRPC) in the US. One or more of the mentioned indications have been approved in more than 100 countries, including the European Union and Japan. 

Related Article: Astellas Clears Primary Endpoints In Prostate Cancer And Menopause Trials

Xtandi Improves Metastasis-Free Survival Compared to Placebo

In the Phase 3 Embark trial assessing Xtandi (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (mmHSPC) with high-risk biochemical recurrence (BCR), Xtandi plus leuprolide, a GnRH receptor agonist showed a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) compared to placebo plus leuprolide. The improvement was also seen in Xtandi monotherapy alone versus placebo, satisfying a secondary endpoint. 

The results noted a positive trend in overall survival (OS), another key secondary endpoint, but the data was not yet mature and will be followed for a final OS analysis, the companies said. Other secondary endpoints showing statistical significance included time to prostate-specific antigen (PSA) progression and time to first use of new antineoplastic therapy. 

No new safety signals were observed in Embark so far, which is consistent with the known safety profile of Xtandi. 

“The topline findings from EMBARK are highly encouraging and we look forward to engaging with health authorities to potentially bring XTANDI to men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology and Rare Disease, Pfizer Global Product Development. 

As Pfizer and Astellas readies their latest data to support a potential FDA regulatory submission for the mmHSPC indication, detailed results from Embark are expected to be presented at a future medical meeting. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
Starboard Value Takes $1 Billion Stake in Pfizer, Eyes Major Overhaul
2024-10-07
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top